Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | — |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | SRC |
| 14 Oct 2025 | Arthur Corbin Cabinet member | Industrial issues | — |
| 14 Oct 2025 | Arthur Corbin Cabinet member | Industrial issues | SRC |
| 25 Sept 2025 | Chiara Galiffa Cabinet member | EU – US relations | SRC |
| 25 Sept 2025 | Chiara Galiffa Cabinet member | EU – US relations | — |
| 08 Sept 2025 | Chiara Galiffa Cabinet member | state of play of the EU US trade relations | — |
| 08 Sept 2025 | Chiara Galiffa Cabinet member | state of play of the EU US trade relations | SRC |
| 25 Apr 2025 | Hoa-Binh Adjemian Head of Unit | Biotech in Serbia | SRC |
| 25 Apr 2025 | Hoa-Binh Adjemian Head of Unit | Biotech in Serbia | — |
| 04 Apr 2025 | Maurice Whelan Head of Unit | Scientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation | — |
| 04 Apr 2025 | Tobias Wiesenthal Head of Unit | Scientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation | SRC |
| 04 Apr 2025 | Maurice Whelan Head of Unit | Scientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation | SRC |
| 04 Apr 2025 | Tobias Wiesenthal Head of Unit | Scientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation | — |
| 27 Jan 2025 | Maurice Whelan Head of Unit | Exploit interest in a scientific roundtable between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation | — |
| 27 Jan 2025 | Tobias Wiesenthal Head of Unit | Exploit interest in a scientific roundtable between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation | SRC |
| 27 Jan 2025 | Maurice Whelan Head of Unit | Exploit interest in a scientific roundtable between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation | SRC |
| 27 Jan 2025 | Tobias Wiesenthal Head of Unit | Exploit interest in a scientific roundtable between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation | — |
| 05 Nov 2024 | Laurent Muschel Acting Director-General | Pipeline presentation | — |
| 05 Nov 2024 | Laurent Muschel Acting Director-General | Pipeline presentation | SRC |
| 15 Apr 2024 | Maroš Šefčovič Executive Vice-President | Meeting WEF CEO Action Group for the European Green Deal | SRC |
| 15 Apr 2024 | Maroš Šefčovič Executive Vice-President | Meeting WEF CEO Action Group for the European Green Deal | — |
| 18 Jan 2023 | Mariya Gabriel Commissioner | EU Innovation Agenda | SRC |
| 18 Jan 2023 | Mariya Gabriel Commissioner | EU Innovation Agenda | — |
| 12 Jul 2022 | Caroline Boeshertz Cabinet member | Pharmaceutical directive | SRC |
Mission & Goals
Roche has grown into one of the world’s largest biotechnology companies, as well as a leading provider of in-vitro diagnostics. Dedicated to scientific excellence, our company develops innovative medicines and diagnostics to save and improve the lives of patients across the globe. More than 44 medicines and diagnostics developed by Roche are included in the WHO Model Lists of Essential Medicines and Tests. For 15 consecutive years, our company was ranked one of the most sustainable companies by the Dow Jones Sustainability Indices. Roche currently employs over 112,000 people in more than 100 countries. In 2025, Roche invested approximately CHF 12.2 billion in R&D and posted sales of CHF 61.5 billion. Genentech, Flatiron Health, Foundation Medicine, and Spark Therapeutics, all based in the US, are wholly owned members of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
EU Legislative Interests
Roche aims to improve patient access to scientific innovation and to strengthen Europe's competitiveness. Our interactions with decision-makers relate to EU legislation and its implementation at national level, e.g. with regard to the European Health Union, Clinical Trials, Cross-Border Healthcare, Access to Medicines, Health Technology Assessment, Pharmaceutical Strategy, Intellectual Property, Critical Medicines and Supply Chain, Orphan Medicinal Products and Pediatric, Pharmaceuticals in the Environment, Sustainability, In-Vitro Diagnostic and Medical Devices, Digital Strategy and AI, Research and Innovation, Biotechnology, Competitiveness, and Trade. Our expertise enables us to contribute to discussions on policy topics of high priority for the company, such as: How to provide patients with timely and safe access to medicines and diagnostics? How to create framework conditions which foster innovation? How to get a fair value for innovative products, devices and services? How to enhance innovative healthcare approaches by making use of AI and data while protecting data privacy?
Communication Activities
Roche provides input to open consultations and participates in events organised by EU institutions and key stakeholders. We also contribute to communication activities and events to address Europe’s health system challenges, for instance the European Health Summit (https://ebsummits.eu/our-summits/european-health/). Moreover, we call for regulatory reforms that specifically address drug-device innovation (https://www.roche.com/stories/roche-in-europe-hub). To this end, we promote our recommendations through various channels, including online publications, social media campaigns, events, and other activities. Lastly, we support communication activities managed by associations such as the European Federation of Pharmaceutical Industries and Associations (EFPIA), MedTech Europe, and patient organisations.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Roche is a member of the European Federation of Pharmaceutical Industries and Associations EFPIA, MedTech Europe, DigitalEurope, and of national industry associations. In addition, Roche is a partner of the European Confederation of Pharmaceutical Entrepreneurs EUCOPE and the European Round Table for Industry ERT, and of patient organisations such as the European Patient Forum EPF, the European Cancer Organisation ECO, and the European Organisation for Rare Diseases EURORDIS.
Organisation Members
Genentech, Flatiron Health, Foundation Medicine, and Spark Therapeutics are wholly owned members of the Roche Group. According to the Transparency Register Guidelines for the 2021 Interinstitutional Agreement, the information published in the present registration also includes their activities.
Additional Information
Roche's entries have been made in line with the greatest possible transparency and are periodically being updated as required. The estimates for this update have been done following the Transparency Register Guidelines for the 2021 Interinstitutional Agreement, and are consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Connected Legislation